|
R-Dihydro-Lipoic Acid — The Optimal
Form of Lipoic Acid
by Jim English
Exciting new research links certain antioxidants
to enhanced mitochondrial energy production. This finding is changing
the way scientists view the interactions of damaging free radicals
and beneficial antioxidants. Among the discoveries produced by this
research are the disease-fighting properties of R-dihydro-lipoic
acid (R-DHLA), a powerful antioxidant that is critically involved
in cellular metabolism. Recent studies suggest that R-dihydro-lipoic
acid may help prevent mitochondrial decay, diabetes, Alzheimer’s
disease, atherosclerosis, and other disorders associated with aging.
Antioxidants are known to play a vital role in
preventing many of the health disorders associated with aging, including
degenerative diseases such as diabetes, Alzheimer’s disease,
and cardiovascular disease.
Medical researchers continue to discover new antioxidant
compounds as well as new applications for these protective nutrients.
A vitamin-like substance known as alpha-lipoic acid is now at the
forefront of antioxidant research. Alpha-lipoic acid was first introduced
as a supplement in the late 1990s. Researchers are uncovering new
applications to add to the already impressive list of therapeutic
uses for alpha-lipoic acid.
A newly available version of alpha-lipoic acid,
called R-dihydro-lipoic acid (R-DHLA), has been shown to offer substantially
greater antioxidant and neuroprotective benefits than previous versions
of alpha-lipoic acid.
Medical researchers initially classified alpha-lipoic acid, which
was virtually unknown until the 1930s, as a new vitamin. Alpha-lipoic
acid eventually was recognized as an essential coenzyme, following
the discovery that it is naturally synthesized in tissues and plays
a vital role in mitochondrial electron transport reactions required
for metabolizing glucose into adenosine triphosphate (ATP) for cellular
energy production. 1
By 1988, alpha-lipoic acid had been revealed as
a powerful biological antioxidant, exhibiting a potential to quench
free radicals equal to that of coenzyme Q10 (CoQ10) and vitamins
C and E. 2 Researchers also discovered
that alpha-lipoic acid is unique in being the only antioxidant known
to work in both fat- and water-soluble tissues. By contrast, the
actions of vitamin C (ascorbic acid) are restricted to watery (aqueous)
tissues, while the actions of vitamin E, which is soluble only in
fat, are restricted to fatty tissues and cellular membranes.
This dual-acting ability allows alpha-lipoic acid
to be easily transported across cellular membranes to neutralize
free radicals in both interior and exterior cellular structures,
leading researchers to refer to alpha-lipoic acid as the “universal
antioxidant.” According to Lester Packer, PhD, professor of
molecular biology at the University of California, Berkeley, alpha-lipoic
acid “could have far-reaching consequences in the search for
prevention and therapy of chronic degenerative diseases . . .”
3
To understand how alpha-lipoic acid and R-dihydro-lipoic acid work
against various degenerative disorders, it is first necessary to
understand how these compounds work in the body—specifically,
how they interact chemically with other critical antioxidants such
as glutathione and vitamins C and E to combat harmful reactive oxygen
species.
Human aging is marked by a sharp decline in the
concentration, synthesis, and recycling of central antioxidants
such as vitamins C and E, CoQ10, and glutathione. This loss of antioxidant
function reduces the body’s ability to protect tissues from
highly reactive free radicals. Left unchecked, free radical proliferation
leads to increased oxidative damage to DNA strands, cell membranes,
mitochondria, and organs. Over time, the cumulative effects of free
radical damage can result in impaired immune function and increased
incidence of cancers and degenerative diseases. In recent years,
one of the leading breakthroughs in antioxidant research is an understanding
of how alpha-lipoic acid recycles vitamins E and C to help control
free radical damage.
Vitamin E is a potent biological antioxidant and
a central component of the antioxidant cycle. Vitamin E protects
fatty tissues, primarily cellular membranes, by quenching free radicals
such as lipid peroxyl and lipid alkoxyl radicals. By donating an
electron to pair up unpaired electrons present in lipid radicals,
vitamin E is transformed into its oxidized form. The oxidized vitamin
E then interacts with vitamin C by accepting one of vitamin C’s
electrons. The process continues as vitamin C, in its oxidized form
as dehydroascorbic acid, accepts an electron from glutathione. Glutathione
is in turn recycled by reduced nicotinamide adenine dinucleotide
phosphate (NADPH). It is at this point in the cycle, however, that
the body’s antioxidant complex runs into a limiting factor
determined by the availability of glutathione.
Glutathione is one of the body’s most important intracellular
antioxidants. In addition to playing a central role in quenching
free radicals, glutathione protects against cataract formation,
en-hances immune function, prevents liver damage, slows the initiation
of cancers, and aids in the elimination of heavy metals. Glutathione
levels can quickly be depleted when the body is exposed to high
levels of oxidative stress during times of illness, infection, trauma,
or surgery. Glutathione deficiency is also seen in cases of low
protein intake, diabetes, liver disease, cataracts, HIV infection,
respiratory distress syndrome, cancer, and idiopathic pulmonary
fibrosis, along with other conditions that produce oxidative stress.
When researchers sought ways to increase cellular
glutathione levels, they encountered a problem. Normally, cellular
glutathione is produced only in the body. When taken orally, glutathione
is largely broken down in the stomach, resulting in modest serum
increases in glutathione but almost no change in intracellular levels
of glutathione.
Dr. Packer and other researchers at UC-Berkeley
have spent almost four decades studying glutathione and antioxidant
recycling. Despite a detailed understanding of the antioxidant regeneration
cycle, Dr. Packer ran into the same problem that had stymied other
researchers when attempting to increase cellular glutathione levels.
This problem was finally solved when he began working with alpha-lipoic
acid, which, according to Dr. Packer, proved to be the missing link.
3 (Editor’s note: The real
problem was found to be that the amino acid building blocks of glutathione
could not be transported across age-damaged cell membranes, and
intracellular glutathione levels decline with age.)
Packer and his team discovered that, in addition
to being a powerful biological antioxidant, alpha-lipoic acid, when
administered orally, quickly crosses cellular membranes to enter
cells where it is rapidly converted into its reduced form, R-dihydro-lipoic
acid (R-DHLA).
It was later discovered that it makes more sense
to take R-dihydro-lipoic acid directly because it is immediately
usable, as the body does not have to convert it from alpha-lipoic
acid. In addition, the synthetic form of alpha-lipoic acid used
in the older studies is a mixture of right-handed and left-handed
molecules. Only the right-handed R- portion of alpha-lipoic acid
is biologically active.
Alpha-lipoic acid, and especially R-dihydro-lipoic
acid, is effective against hydroxyl radicals, peroxynitrite hydrogen
peroxide, and hypochlorite. In addition, alpha-lipoic acid has been
shown to regenerate and elevate intracellular glutathione levels,
thereby participating in the recycling of the antioxidant complex.
4,5
Initial research revealed that, in addition to
conferring general health benefits like other antioxidant supplements,
alpha-lipoic acid possesses properties that can be helpful in managing
a wide range of diseases. According to Dr. Packer, “Alpha-lipoic
acid could have far-reaching consequences in the search for prevention
and therapy of chronic degenerative diseases such as diabetes and
cardiovascular disease, and because it’s the only antioxidant
that can easily get into the brain, it could be useful in preventing
damage from a stroke.” 3
Alpha-lipoic acid has been shown to be
particularly helpful for conditions arising from diabetes, and has
been used in Europe for over 30 years for diabetic complications
caused by overproduction of reactive oxygen species and nitrogen
radicals. 6 Alpha-lipoic acid has
also been shown to aid in increasing glucose uptake in skeletal
muscles, as well as in enhancing insulin-stimulated glucose disposal.
7,8
 |
Alpha-lipoic acid has proven especially effective
in treating diabetes-related neuropathy, the functional or pathological
changes in the peripheral nervous system that can include pain,
tingling, or sensory abnormalities. In one study, German scientists
tested a group of 80 diabetic patients who were randomly assigned
to four groups of 20 patients each. Each group received alpha-lipoic
acid, selenium, vitamin E, or placebo. After three months, the researchers
found that treatment with 600 mg of alpha-lipoic acid daily resulted
in significant improvements in two markers of diabetes (thiobarbituric
acid reactive substances and urinary albumin excretion rates). The
researchers also noted significant improvements in neuropathy, leading
them to conclude that alpha-lipoic acid was effective in reducing
late diabetic complications. 9
In a second study, 328 non-insulin-dependent diabetic
patients diagnosed with symptomatic peripheral neuropathy (causing
pain, burning, or numbness) were treated either with alpha-lipoic
acid or placebo. At the study’s end, pain scores had declined
significantly in the group treated with alpha-lipoic acid, leading
researchers to conclude that alpha-lipoic acid was effective in
reducing symptoms of diabetic peripheral neuropathy, without side
effects. 10
Acquired immunodeficiency syndrome (AIDS) results from infection
with the human immunodeficiency virus (HIV-1). Certain regions of
HIV-1 DNA contain binding sites for nuclear factor-kappa beta, a
transcriptional activator with a major role in the regulation of
HIV-1 gene expression. Research has shown that alpha-lipoic acid
inhibits the replication of HIV-1 and other viruses by blocking
reactive oxygen species used in signal transduction pathways that
lead to activation of nuclear factor-kappa beta. Dr. Packer and
his colleagues theorized that alpha-lipoic acid, by eliminating
reactive oxygen species, may prevent activation of nuclear factor-kappa
beta and subsequently halt HIV transcription. 11
When Dr. Packer and his team tested their theory by exposing cells
to alpha-lipoic acid, they discovered that alpha-lipoic acid was
able to completely inhibit nuclear factor-kappa beta to block activation
of the gene sequence that allows the AIDS virus to reproduce. These
results, the authors suggested, “indicate that alpha-lipoic
acid may be effective in AIDS therapeutics.”
In a related finding, when Japanese researchers
exposed cells infected with HIV-1 to alpha-lipoic acid, “initiation
of HIV-1 induction by [tumor necrosis factor-alpha] was completely
abolished.” The scientists concluded that their findings confirm
“the efficacy of alpha-lipoic acid as a therapeutic regimen
for HIV infection and [AIDS].” 12
Natural alpha-lipoic acid, or R-lipoic acid, is present in exceedingly
tiny amounts in, and tightly bound to, mitochondrial complexes in
animal and plant tissues. Because of the extreme difficulty and
high cost of isolating natural R-lipoic acid, early studies were
conducted with synthetic alpha-lipoic acid. Unlike R-lipoic acid,
synthetic lipoic acid comprises a fifty-fifty mixture of two forms
of alpha-lipoic acid: R-lipoic acid and S-lipoic acid. The R- and
S- forms of alpha-lipoic acid are isomers—identical chemical
structures, with the three-dimensional atomic arrangements reversed
to form mirror images of each other.
Initial studies with synthetic alpha-lipoic acid
helped scientists to understand its antioxidant-recycling and energy-production
properties. When pure samples of the natural R- form of lipoic acid
version became available, however, researchers quickly discovered
that the body has a strong preference for R-lipoic acid. German
researchers reported that, unlike the natural R-lipoic acid, synthetic
lipoic acid does not improve ATP synthesis in isolated cells. Furthermore,
whereas the natural R- form was shown to increase membrane fluidity
and transport, the synthetic form was far less effective in doing
so. 13
Continuing experimentation revealed that R-lipoic
acid is more biologically active and offers greater antioxidant
and neuroprotective benefits at substantially lower doses than the
synthetic forms of lipoic acid. This became apparent when researchers
compared the effects of natural and synthetic lipoic acid in the
prevention of cataracts. Half of all healthy adults over 65 will
eventually develop cataracts, an opacity of the eye lens that can
cause vision impairment or blindness. For those with diabetes, the
odds of developing cataracts are substantially higher, as eye lenses
are especially susceptible to damage from elevated glucose levels.
Researchers have found that R-lipoic acid may aid in preventing
cataracts and their complications by increasing levels of glutathione,
ascorbate, vitamin E, and certain protective enzymes in lens tissues.
In one study, researchers induced cataracts by
incubating rat lenses in glucose to mimic the damaging processes
seen in diabetes. R-lipoic acid was shown to be highly effective
in preventing cataract formation, while synthetic lipoic acid was
only half as effective at protecting lens cells. 14
In a follow-up study, when eye lenses were exposed to either R-lipoic
or synthetic lipoic acid, glutathione concentrations in the lenses
incubated with the natural form were significantly higher than those
incubated with the synthetic form. These data showed that R-lipoic
acid was more effective in maintaining glutathione levels and protecting
the lens from damage. 15
 |
Age-related declines in physical activity and
mental function are partly the result of a drop in mitochondrial
energy production. Mitochondria are known to lose efficiency with
age due to the oxidation of proteins, lipids, DNA, and RNA. 16
Researchers led by Bruce Ames, PhD, professor of biochemistry and
molecular biology at the University of California, Berkeley, have
shown that the age-related decay of mitochondrial function can be
partially reversed in older animals following treatment with R-lipoic
acid or a combination of R-lipoic acid and acetyl-L-carnitine. In
their study, older rats receiving either R-lipoic acid or a combination
of R-lipoic acid and acetyl-L-carnitine showed signs of reduced
lipid peroxidation and improved memory. 17
Over time, oxidative stress in brain cells damages
mitochondria, proteins, and nucleic acids, particularly in the region
of the hippocampus. Left unchecked, these changes can contribute
to impaired memory and loss of cognitive functions. In a groundbreaking
study designed to mimic age-related loss of cognitive function and
memory in humans, Dr. Ames and his colleagues treated older rats
with either R-lipoic acid or a combination of R-lipoic acid and
acetyl-L-carnitine. Dietary supplementation with R-lipoic acid and/or
acetyl-L-carnitine was shown to significantly improve both spatial
and temporal memory performance. Additionally, both R-lipoic acid
and R-lipoic acid/acetyl-L-carnitine were found to significantly
reduce the extent of oxidized RNA. Follow-up electron microscopic
studies in the hippocampus showed that R-lipoic acid and R-lipoic
acid/acetyl-L-carnitine reversed age-associated mitochondrial structural
decay. The study results suggest that R-lipoic acid, either alone
or in combination with acetyl-L-carnitine, may aid in lowering oxidative
damage and improving mitochondrial function, thus improving memory
and cognitive functions in aging humans. 18
In the body, alpha-lipoic acid occurs in two forms: R-lipoic acid
and R-dihydro-lipoic acid (R-DHLA). The two make up a “redox
couple.” Oxidation reduction (redox reactions) involves the
transfer of an electron from a donor to an acceptor. When the donor
loses an electron, it is transformed from its reduced form to its
oxidized form; conversely, when an acceptor gains an electron, it
changes from its oxidized form to its reduced form. Together, the
oxidized and reduced forms of a redox component are said to form
a redox couple.
In the case of R-lipoic acid, when it donates an electron to R-dihydro-lipoic
acid, the R-dihydro-lipoic acid is oxidized back into R-lipoic acid,
and the R-lipoic acid is then reduced back into R-dihydro-lipoic
acid. As the two forms swap electrons, they rapidly convert. Many
of the properties of lipoic acid depend on this ability to rapidly
swap electrons, and most health benefits are observed regardless
of which form is used. As always, however, there are important exceptions.
As researchers continued to study lipoic acid, they discovered that
R-dihydro-lipoic acid exerts a number of antioxidant and neuroprotective
actions that are not seen with alpha-lipoic acid. One important
difference is that while both alpha-lipoic acid and R-dihydro-lipoic
acid effectively scavenge a number of radical species (hydroxyl
radicals, nitric oxide radicals, peroxynitrite, hydrogen peroxide,
and hypochlorite), only R-dihydro-lipoic acid has been shown effective
against superoxide and peroxyl reactive oxygen species. 19
Moreover, whereas alpha-lipoic acid and R-dihydro-lipoic
acid both regenerate endogenous antioxidants and prevent oxidative
stress, only R-dihydro-lipoic acid has been shown capable of actually
repairing oxidative damage. Alpha-1 antiprotease (alpha 1-AP) is
a physiologically essential macromolecule that helps lung tissue
remain elastic. Oxidized alpha 1-AP has been implicated in the etiology
of certain lung diseases, such as cystic fibrosis. German researchers
discovered that R-dihydro-lipoic acid was effective in reversing
the oxidative damage to alpha 1-AP, leading them to conclude, “[R-]dihydro-lipoic
acid may exert a curative effect in diseases accompanied by oxidative
stress.” 20
R-dihydro-lipoic acid has also been shown to interact
with and enhance the antioxidant effects of CoQ10. By donating an
electron to oxidized CoQ10, R-dihydro-lipoic acid has been demonstrated
to prevent the formation of damaging pro-oxidants, while maintaining
CoQ10 in its active antioxidant form to prevent peroxidation of
susceptible biomembranes. 21
Alzheimer’s disease is a progressive neurodegenerative disorder
that typically develops in people aged 50 or older. Its hallmarks
include oxidative stress and energy depletion. German researchers
theorized that alpha-lipoic acid’s positive effects on glucose
metabolism might assist in treating Alzheimer’s. They administered
600 mg of alpha-lipoic acid daily to nine Alzheimer’s patients
in an open study for periods lasting close to a year. Alpha-lipoic
acid treatment led to a stabilization of cognitive functions in
the study group, determined by constant scores in two neuropsychological
tests. Despite the limited sample size, the research team reported
that treatment with alpha-lipoic acid might be a successful neuroprotective
therapy for Alzheimer’s disease and related dementias. 22
In a second study, researchers at the Sanders-Brown
Center on Aging at the University of Kentucky Chandler Medical Center
have shown that R-dihydro-lipoic acid protects cortical neurons
from the toxic effects of two oxidative substances implicated in
Alzheimer’s disease. The researchers found that cortical neurons
were significantly protected by R-dihydro-lipoic acid following
exposure to iron/hydrogen peroxide and amyloid beta-peptide. Interestingly,
whereas pretreatment with alpha-lipoic acid protected cells subsequently
exposed to iron/hydrogen peroxide, there was no protection noticed
in cells exposed to alpha-lipoic acid and iron/hydrogen peroxide
at the same time. Reviewing the results of the study, the authors
concluded, “Treatment of cortical neurons with [R-]dihydro-lipoic
acid significantly protected glucose transport against [iron/hydrogen
peroxide] or beta-mediated decreases, although treatment with alpha-lipoic
acid did not provide protection. These data suggest that R-dihydro-lipoic
acid, the reduced form of R-lipoic acid, significantly protects
against both [amyloid beta] and [iron/hydrogen peroxide] mediated
toxicity.” 23
Atherosclerosis is theorized to begin when low-density lipoprotein
(LDL) particles circulating in the blood are damaged by lipid peroxidation.
When the oxidatively modified LDL particles become implanted beneath
the endothelial layers lining arterial walls, they are recognized
as foreign invaders. This triggers apoptosis, or the cellular suicide
of artery cells. A build-up of foam cells later causes bulges in
the artery wall and atherosclerotic plaque develops. In-vitro experiments
have shown that R-dihydro-lipoic acid—but not alpha-lipoic
acid — can counteract lipid peroxidation of LDL particles,
demonstrating a potential therapeutic effect for the early prevention
of atherosclerosis. In the same study, R-dihydro-lipoic acid—but
not alpha-lipoic acid — was shown to readily reduce iron and
scavenge free radicals in a model of atherosclerosis, demonstrating
a potential therapeutic effect for the early prevention of inflammatory
processes implicated in cardiovascular disease. 24
Heart attack and stroke are significant causes of mortality and
disability. Therapeutics that can optimize healing from these events
thus may be valuable aids in restoring health and function. When
blood flow is restored following a heart attack or stroke, cells
previously deprived of oxygen generate a flood of free radicals
that inflict damage to surrounding tissues that is more severe than
that caused by the original trauma. When researchers treated isolated
rat hearts with lipoic acid (given in the form of R-dihydro-lipoic
acid), mitochondrial function significantly improved. This resulted
in significantly higher ATP levels in the heart tissue compared
to untreated hearts. 25
In one study, a combination of R-dihydro-lipoic
acid and vitamin E was shown to synergistically improve cardiac
functional recovery during post-ischemic reperfusion or post-hypoxic
reoxygenation of working rat hearts. After 30 minutes of oxygen
deprivation (hypoxia), hearts treated with R-dihydro-lipoic acid
showed significantly higher levels of ATP following reoxygenation
than did untreated hearts. 26 R-dihydro-lipoic acid combined with
vitamin E may therefore help guard against damage to heart tissue
inflicted by cardiac events.
According to Dr. Packer, “Just 10 years ago, scientists had
a simplistic view of free radicals and antioxidants. Today, knowledge
of a global antioxidant network has emerged which is linked to the
metabolic energy-producing process—a new perspective that
is leading to an explosion of basic research and therapeutic studies.”
3
R-dihydro-lipoic acid is a powerful new supplement
that sits at the forefront of this new wave of antioxidant research.
As a powerful biological antioxidant involved in cellular metabolism
and the recycling of endogenous antioxidants, R-dihydro-lipoic acid
has been shown to aid in the prevention of numerous disorders associated
with aging and oxidative stress, including diabetes, Alzheimer’s
disease, and atherosclerosis.
References
1. Reed LJ, DeBusk BG, Gunsalus IC, Hornberger
CS Jr. Crystalline alpha-lipoic acid; a catalytic agent associated
with pyruvate dehydrogenase. Science. 1951 Aug 27;114(2952):93-4.
2. Bast A, Haenen GR. Interplay between lipoic acid and glutathione
in the protection against microsomal lipid peroxidation. Biochim
Biophys Acta. 1988 16;963(3):558-61.
3. Available at: http://www.berkeley.edu/news/media/releases/96legacy/releases.96/14316.html.
Accessed October 22, 2004.
4. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological
antioxidant. Free Radic Biol Med. 1995 Sep;19(2):227-50.
5. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic
antioxidant alpha-lipoic acid. Free Radic Biol Med. 1997;22(1-2):359-78.
6. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid
in the prevention of diabetes complications. Nutrition. 2001 Nov;17(10):888-95.
7. Evans JL, Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant
that improves insulin sensitivity in patients with type 2 diabetes.
Diabetes Technol Ther. 2000 Autumn;2(3):401-13.
8. Jacob S, Henriksen EJ, Tritschler HJ, Augustin HJ, Dietze GJ.
Improvement of insulin-stimulated glucose-disposal in type 2 diabetes
after repeated parenteral administration of thioctic acid. Exp Clin
Endocrinol Diabetes. 1996;104(3):284-8.
9. Kahler W, Kuklinski B, Ruhlmann C, Plotz C. Diabetes mellitus
— a free radical-associated disease. Results of adjuvant antioxidant
supplementation. Z Gesamte Inn Med. 1993 Jun;48(5):223-32.
10. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic
diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic
acid. A 3-week multicentre randomized controlled trial (ALADIN Study).
Diabetologia. 1995 Dec;38(12):1425-33.
11. Suzuki YJ, Aggarwal BB, Packer L. Alpha-lipoic acid is a potent
inhibitor of NF-kappa B activation in human T cells. Biochem Biophys
Res Commun. 1992 Dec 30;189(3):1709-15.
12. Merin JP, Matsuyama M, Kira T, Baba M, Okamoto T. Alpha-lipoic
acid blocks HIV-1 LTR-dependent expression of hygromycin resistance
in THP-1 stable transformants. FEBS Lett. 1996 Oct 23;394(1):9-13.
13. Hofmann M, Mainka P, Tritschler H, Fuchs J, Zimmer G. Decrease
of red cell membrane fluidity and -SH groups due to hyperglycemic
conditions is counteracted by alpha-lipoic acid. Arch Biochem Biophys.
1995 Dec 1;324(1):85-92.
14. Kilic F, Handelman GJ, Serbinova E, Packer L, Trevithick JR.
Modelling cortical cataractogenesis 17: in vitro effect of a-lipoic
acid on glucose-induced lens membrane damage, a model of diabetic
cataractogenesis. Biochem Mol Biol Int. 1995 Nov;37(2):361-70.
15. Kilic F, Handelman GJ, Traber K, Tsang K, Packer L, Trevithick
JR. Modelling cortical cataractogenesis XX. In vitro effect of alpha-lipoic
acid on glutathione concentrations in lens in model diabetic cataractogenesis.
Biochem Mol Biol Int. 1998 Nov;46(3):585-95.
16. Liu J, Atamna H, Kuratsune H, Ames BN. Delaying brain mitochondrial
decay and aging with mitochondrial antioxidants and metabolites.
Ann N Y Acad Sci. 2002 May;959:133-66.
17. Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative
decay: improvement of carnitine acetyltransferase substrate-binding
affinity and activity in brain by feeding old rats acetyl-L-carnitine
and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA. 2002 Mar 19;99(4):1876-81.
18. Liu J, Head E, Gharib AM, et al. Memory loss in old rats is
associated with brain mitochondrial decay and RNA/DNA oxidation:
partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic
acid. Proc Natl Acad Sci U S A. 2002 Mar 19;99(4):2356-61.
19. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant
lipoic acid. Gen Pharmacol. 1997 Oct;29(3):315-31.
20. Biewenga GP, Veening-Griffioen DH, Nicastia AJ, Haenen GR, Bast
A. Effects of dihydro-lipoic acid on peptide methionine sulfoxide
reductase. Implications for antioxidant drugs. Arzneimittelforschung.
1998 Mar;48(2):144-8.
21. Kozlov AV, Gille L, Staniek K, Nohl H. Dihydro-lipoic acid maintains
ubiquinone in the antioxidant active form by two-electron reduction
of ubiquinone and one-electron reduction of ubisemiquinone. Arch
Biochem Biophys. 1999 Apr 1;363(1):148-54.
22. Hager K, Marahrens A, Kenklies M, Riederer P, Munch G. Alpha-lipoic
acid as a new treatment option for Alzheimer type dementia. Arch
Gerontol Geriatr. 2001 Jul;32(3):275-82.
23. Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against
amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha
lipoic acid. J Alzheimers Dis. 2003 Jul;5(3):229-39.
24. Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuccurullo
F. Dihydro-lipoic acid inhibits 15-lipoxygenase-dependent lipid
peroxidation. Free Radic Biol Med. 2003 Dec 15;35(10):1203-9.
25. Haramaki N, Assadnazari H, Zimmer G, Schepkin V, Packer L. The
influence of vitamin E and dihydro-lipoic acid on cardiac energy
and glutathione status under hypoxia-reoxygenation. Biochem Mol
Biol Int. 1995 Nov;37(3):591-7.
26. Haramaki N, Packer L, Assadnazari H, Zimmer G. Cardiac recovery
during post-ischemic reperfusion is improved by combination of vitamin
E with dihydro-lipoic acid. Biochem Biophys Res Commun. 1993 Dec
15;196(3):1101-7.
This article appears in the
Februay 2005 issue of Life Extension. Reprinted with permission
of LE Publications, Inc. |